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INTRODUCTION 
      Cardiac Autonomic neuropathy common and worst   complication 
of diabetes mellitus. Diabetic cardiac autonomic neuropathy (CAN),  
major complication seen  in one-sixth of insulin dependent type 1 diabetes 
and one-third of non insulin dependent diabetic patients, related with 
increased morbidity.  
 
CAN is related with  poor prognosis and may lead to postural 
hypotension, exertional intolerance, enhanced intraoperative instability,   
increased  silent myocardial infarction  ischemia and left ventricular (LV) 
dysfunction.  
Diabetics with cardiac autonomic neuropathy are  prone for sudden 
cardiac death  due to silent myocardial ischemia   or due to  ventricular 
arrhythmias.CAN increases with  obesity, age, poor glycemic control, and 
may be with  duration of diabetes  
The association between CAN and QT interval prolongation  
demonstrated in more studies and it  predispose to sudden cardiac death in 
diabetes. Increased QT dispersion(QTD) is suggested as  marker of 
diabetic cardiac autonomic neuropathy.  
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In one study Sacre et al.  estimated the association of CAN with LV 
dysfunction. This author  found  patients with  CAN had  systolic and 
diastolic dysfunction at rest, and systolic dysfunction after exercise. They  
found  association between diastolic function and CAN, not dependent on 
metabolic factors and other   factors contributing  to LV dysfunction. The 
relative dominance of sympathetic activity at  onset of CAN will stimulate  
renin-angio tensin aldosteronesystem(RAAS), which  increases  
hemodynamic stresses and energy requirements of  left ventricle by 
sodium retention and peripheral vasoconstriction. It may  exert direct 
noxious effects on cardiomyocytes (apoptosis of cardiomyocytes and 
regression to  fetal  phenotype)  changes in  nature of  extracellular 
matrix(ECM) by stimulation of myocardial fibrosis, which further alter 
architecture and impair  performance of left ventricle.  
Such sympathetic overactivity, in association with regional 
myocardial autonomic  denervation present in  more advanced stage of 
CAN, have been recently shown that may lead to decreased coronary 
blood flow capacity and diastolic dysfunction in a  insulin independent 
diabetic patients with features of early micro vascular changes. The 
confirmation of   presence of CAN in a otherwise healthy type 2 diabetes  
patients, and its independent relation with resting  diastolic 
dysfunction(DD), is important. Most of the research data regarding QT 
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interval and diabetic CAN are found in type 1 diabetes with only very few 
studies in type 2 diabetes. This study is aimed to find out the association 
of corrected QT (QTc) interval and QTc dispersion with diabetic cardiac 
autonomic neuropathy in type 2 diabetes attending diebetic op or medical 
op at ggh so that we can found the subset of diabetic patients who are at  
risk for sudden  death and to find correlation between CAN and diastolic 
dysfunction-the basis for non ischemic diabetic cardiomyopathy. 
Several treatment options including graded exercise, cardioactive 
drugs, and intensive medication for contolling many  risk factors of CAN 
which are joined with  treatment  for macrovascular complication that  
have been shown to improve functional deficiency in  autonomic nervous 
system(ANS). Therefore, noninvasive detection of early stages of CAN 
using QT dispersion and 2D echo may necessitates  the need for definite 
control  of cv  risk factors, so by  decreasing risk of early mortality. 
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AIMS AND OBJECTIVES 
 
 To study the utility of prolongation of corrected QT interval in 
the ECG to diagnose CAN in patients with diabetes mellitus and 
to study the prevalence of diastolic dysfunction-the basis for non 
ischemic cardiomyopathy? 
 To study the prevalence and risk factors for cardiac autonomic 
neuropathy 
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REVIEW OF LITERATURE 
VARIOUS  DESCRIPTION OF DIABETES MELLITUS (DM) 
EGYPTIAN   DESCRIPTION  
 
Historical clinical description of Diabetes Mellitus found in the 
Ebers Papyrus,  18th Egyptian Dynasty of about 1500 BC. 
 
 
Ebers papyrus : early clinical description of diabetes (Egyptian, 1500 BC) 
 
INDIAN DESCRIPTION  
In India described as “Sweetness of urine” . 
 
GREEKS DESCRIPTION  
3rd century Greeks only first used term diabetes 1100 years 
later. 
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           Aretaeus of Cappadocia in Asia Minor, in the 1st century AD 
given the first description .He is the first physician to describe 
diabetes formally. He explained it as “ passing of copious amounts of 
urine and the loss of body flesh” 
 
Willis in 1674 who described “sweetness of the urine” and 
found that it was secondary to sweetness in the blood. 100 years later 
it was identified that  sweetness may due to increased level of sugar, 
and  50 years later this was found as “ glucose” 
 
In  1890 von Mering and Minkowski  identified pancreatic 
factor   after identification of glycosuria following pancreatectomy in 
dogs. In 19th century  it was thought that diabetes may be 
multifactorial not a single disease. Bernard identified the biochemical 
details of diabetes  as  the production of glucose by the liver 
.Association of coma with acidosis also found during this period . 
 
           In 1922   Ideas of Banting, with  technical help of Best, facilities 
and support of MacLeo and biochemical expertise of Collip   produce  
adequately pure and more potent preparation of bovine insulin . 
Following which long acting preparations of insulin came into 
market after decades by Hagedorn and Hallas-Moller,  . 
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TECHNICAL MILESTONES IN THE MANAGEMENT OF 
 
DIABETES 
 
 
Year Worker(s) Milestone 
   
1797 Rollo Dietary management 
   
1913 Alien Severe calorie restriction 
   
1921 Banting, Best, Collip, Macleod Isolation and use of insulin 
   
 Hagedorn and colleagues Protamine-insulin complexes 
1936 
  
  
used 
   
1939 Loubatieres Discovery of Sulphonylureas 
   
 
Jorgensen and Colleagues Highly purified insulin 
1970 
  
  
available 
   
 Sonksen and colleagues Self blood glucose monitoring 
1976 
  
 
Walford and Colleagues 
 
   
 Koenig and colleagues Glycosylated haemoglobin to 
1976 
  
  
Monitor control 
   
1979 Goeddel and colleagues Genetically engineered insulin 
   
 
Many researchers Microcomputers in diabetes 
1980 
  
  
management 
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DEFINITION  
                Diabetes occurs because of “the presence/absence of 
factors that act against  insulin or lack of insulin”. Due to insufficient 
insulin action resulting in  increase in blood sugar  level 
(hyperglycaemia) .Patient develop diabetic acidosis due to 
accumulation of ketone bodies resulting in morbidity 
 
DIAGNOSIS  
              It is diagnosed by blood glucose level done in accredited lab  
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CLASSIFICATION OF DIABETES MELLITUS 
 
Diabetes is divided into four main groups as type 1, type 2, 
other specific types, and Gestational diabetes. Type 1 diabetes  
because of absolute lack of insulin results from pancreatic islet cell 
destruction mostly an autoimmune process. They tend to develop 
ketoacidosis and require insulin therapy. Type 2 diabetes the most 
common type of diabetes, is a heterogeneous disorder most 
commonly associated with insulin resistance mechanisms with 
relative insulin deficiency due to abnormalities of insulin secretion . 
 
 
 
 
 
TYPE 1 DIABETES MELLITUS  
Results from an autoimmune attack triggered by many factors 
such as   environmental and genetic in a susceptible  individual .  It  
begins very  early in life . 
13 
 
 
TYPE 2   DIABETES MELLITUS 
 
 
 
 
 
TYPE 2 DM  NATURAL HISTORY 
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PATHOGENESIS OF TYPE 2 DM  
There  are  numerous causes for type 2 DM  . The underlying 
mechanism is  either due to diminished insulin secretion— an  islet  
cell defect, associated with increased peripheral resistance to  action 
of insulin .It results in decreased peripheral glucose  uptake, or  
increased hepatic glucose output. Probably as many as 98% of  Type 
2 diabetic patients are “idiopathic”—that is, no specific causative 
defect has been identified. 
 It  is  a slowly progressive   disease . Some individual above 
twenty years of age  who  presented insulin independent diabetes  
 become   insulin dependent It is known as  “ latent autoimmune 
diabetes of  adulthood “  (LADA)   They have autoantibodies against 
insulin.   
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RISK FACTORS FOR TYPE 2DM  
 
 
 
OBESITY  
 
 
                        Natural history of  Diabetes Mellitus 
 
 Fat distribution is related  to  development of diabetes 
mellitus. Waist hip ratio is .8 in males and .9 in females are more 
akin to development of this diseases. Many studies showed the 
correlation . use of  leptin as a marker for this studies It is under trial 
17 
 
 
 
TYPE 2 DM IN CHILDREN AND YOUNG ADULTS 
   
It is  recently  estimated that 8% and 45 % are found to be type 
2 DM in U.S. diagnosed at the age of 12 -14 years .Most of the 
children are girls associated with  obesity and  positive  family 
history .  
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MITOCHONDRIAL DIABETES  
           
Rare  form of type 2 DM seen in young and thin individuals 
associated with microvascular complications . They do better with 
sulphonyureas . It is related to A3243G DNA  mutation . 
 
INSULIN RESISTANCE DIABETES  
 
          They often associated with acanthosis nigricans ,lipodystrophy   
and dyslipidemia. Type A due to receptor  defect  . IgG 
autoantibodies against insulin receptor is seen in type b diabetes  
 
PREVALENCE  
 
Worldwide,  incidence of  Type 2 diabetes is rising very 
rapidly: , it was estimated that about 140 million people are diabetics 
in the year of 1996 . This estmates doubles in another 30 years 
mainly in developin and under developed countries 
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GEOGRAPHICAL  VARIATIONS  
       
         More prevalent in Asian and African- carribean    and in some    
inner  urban areas .Asian people have higher incidence of diabetic  
nephropathy (DN) and coronary artery disease (CAD) .      
 
 
 
DIABETIC COMPLICATIONS  
 
Diabetes affect almost every organ in the body . It is divided 
into micro and macro vascular complications . 
 
20 
 
PATTERN OF PRESENTATION  
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AIMS OF TREATMENT  
HEALTHY LIFESTYLE  
         “Diabetes is easy to diagnose, but can be managed with 
negligent ease by those inclined to do so” RB Tattersall, 1990 
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AUTONOMIC NERVOUS SYSTEM (ANS)  
 
The autonomic nervous system send sensory impulses from all 
of the organs  through nerves to  brain such as medulla, pons and 
hypothalamus. They do not reach our consciousness, but elicit  
automatic or reflex responses through  efferent autonomic nerves, 
eliciting appropriate reflexes of the heart,  vascular system and all 
organs of  body to variations in surrounding temperature, lying 
supine or standing postures, food intake,  other changes to which all 
the individuals are exposed. Two components of ANS are 
sympathetic and  parasympathetic system . 
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FUNCTION OF AUTONOMIC NERVOUS SYSTEM  
 
Function of ANS is regulation of internal organs . when  there 
is ANS dysfunction ,function of maintaining homeostasis and 
adapting to stress is not effective .  
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FUNCTION OF ANS  
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AUTONOMIC DYSFUNCTION 
Autonomic  dysfunction  is part of acute or chronic peripheral 
neuropathies (e.g: Diabetic, alcoholic-nutritional, Amyloidosis, 
Gullain-Barre syndrome, infections, heavy metal toxic and 
porphyrias).  
 
CLINICAL FEATURES OF AUTONOMIC DYSFUNCTION  
 
 
 
CARDIOVASCULAR  SYSTEM   
POSTURAL HYPOTENSION  
Systolic blood pressure fall more than 20mmHg on standing 
for three minutes is defined as postural hypotension. Symptoms 
developed when fall is more than 30mmHg .  
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TREATMENT OF HYPOTENSION  
 
                  
       
GUSTATORY SWEATING  
 
Gustatory sweating. The sweating is highlighted by strarch – iodide powder 
While eating tasty food is an early sign of autonomic neuropathy.  
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DIAGNOSIS OF CAN  
Bedside tests for  CVS are used to exclude  autonomic 
neuropathy. Cardiac autonomic function test are done using cans 
analyser  which is shown in the figure. 
 .
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CANS ANALYSER 
 
 
CLINICAL TESTING OF AUTONOMIC NEUROPATHY  
 
 
First  rule out end organ damage before subjecting the patient 
to CAN tests. It is  valid,   significant time tested procedures to 
diagnose autonomic neuropathy noninvasively more specific. Co-
morbid illness, usage of drugs like anti-histamines, antidepressants, 
anti-tussives, aspirin should not be there. Patients instructed  to 
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abstain from smoking and drinking coffee at least one hour before the 
test. 
Heart rate response to deep breathing 
Heart rate changes  with respiration . This is determined by 
parasympathetic system. To evaluate this response, patient is 
instructed to lie down quietly and is asked  to take slow deep breaths 
at a rate of six per minute. ECG monitors maximum and minimum 
heart rate.  
Heart rate response to standing 
Patient is asked to get up from supine position and heart rate to 
this response is calculated. After standing, the heart rate normally 
increases and is maximum at about fifteenth beat after attaining erectl 
posture. The heart rate then starts falling and is minimum at about 
thirtieth beat. Hence R-R variation between fifteen and thirtieth beats 
are monitored. 
Valsalva maneuver 
Originally used as a method to expel pus from middle ear 
which is done by blowing and straining with closed nose and mouth. 
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The patient first takes a deep breath and then expires forcibly against 
a closed glottis for a period of ten to twenty seconds.  
Alternatively to test for autonomic function, patient needs to 
blow into a sphygmomanometer such that a pressure level of at least 
forty mms is maintained for thirty seconds. Valsalva maneuver is 
associated with a short duration increase of intraocular pressure as 
well as intra cranial pressure. This leads to a risk of hemorrhage 
within the eye and dislocation of lens. The risk is somehow known to 
be low because similar increase in pressure occur in day to day 
activities also.  
There are four phases explained as normal response to valsalva 
maneuver.  
Phase 1: at the beginning of straining, there is a short duration 
of increase in intrathoracic pressure which causes increased BP and 
decreased heart rate. This happens because the elevated pressure 
compresses the aorta thereby propelling blood into peripheral 
circulation.  
Phase 2: This is the straining phase where there is decrease in 
BP initially which later is recovered. There is associated reflex 
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tachycardia, stroke volume reduces because of decrease in venous 
return. 
Phase 3:  cessation of straining in this phase causes an increase 
in venous return. There is an abrupt but transient fall in BP and 
increased heart rate. 
Phase 4: this is the overshoot phase where the event returns to 
pre-valsalva state after about 6 to 8 beats. There is an initial 
overshoot of BP wide pulse pressure and also reflex bradycardia. 
ECG tracing during the maneuver are taken to calculate ratio between 
longest and shortest R-R interval. Normal is 1.6.  
Systolic blood pressure response to standing 
Otherwise known as postural hypotension and has been 
discussed earlier. 
Diastolic BP response to sustained handgrip 
A hand grip dynamometer is used to detect increase of systolic 
and diastolic BP and chang in heart rate. The patient is supposed to 
squeeze the dynamometer to its maximum followed by a slow release 
to keep it at a level of at least 30 % of maximum for 120 to 180 
seconds. Normally after the hand grip is released, there will be an 
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increase of diastolic BP to more than 16 mm of Hg. Abnormal 
response is less than 10 mm of Hg increase in BP. 
We look for reduced variability (less of a change in heart rate), 
a sign that the patient’s heart response, as provided by the body’s 
autonomic control center, is not adequate. At least two tests must be 
performed in order for the test to be conclusive. Sometimes one test 
result may be abnormal, but the second test result turns out normal.  
This is because some heart rate variability tests are more 
sensitive to earlier autonomic nervous system dysfunction than 
others. This is also due to the fact that test results are based on a 
combination of activities within the body, which are influenced 
differently in each patient. As a general rule, the more tests that result 
in abnormal results, the more severe the end organ damage is to the 
autonomic nervous system. 
 Perhaps the most important things we can do for our patients 
with diabetes are to make them aware of autonomic neuropathy, to let 
them know whether they have it, and to help them keep blood sugar 
levels in an acceptable range.  
34 
 
Doing so not only helps reduce the risk of heart disease, but 
also lowers the risk of diabetic eye, kidney and nerve disease, each of 
which patients  want to avoid.  
Diabetic autonomic neuropathy has been called a "silent 
killer," because so few patients realize that they suffer from it, and 
yet its effects can be so lethal. With a brief, 15-minute test that we 
can administer in the office, and some relatively modest 
interventions, we can help many patients live longer, healthier lives. 
PATHOGENESIS OF DAN: 
Autonomic dysfunction that accompanies diabetic neuropathy 
is the one that has extensively evaluated.Several different factors 
have been implicated in this pathogenic process. 
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DIABETIC CARDIOMYOPATHY  
Cardiovascular morbitidy and mortality accounts for 65% in 
diabetic patients . Hence  ADA accepted it as coronary equivalents. It 
affects heart in three ways .1)atherosclerosis related CAD 2) Cardiac 
autonomic neuropathy 3) Diabetic cardiomyopathy (DbCM) . Third 
entity is poorly understood by Physicians and Diabetologists . 
Rubler et al first described DbCM  as “Myocardial dysfunction 
in the absence of valvular heart diseases coronary heart diseases and 
hypertension”. Heart failure is common complication in diabetic 
patients . It affect the quality of life . Hence it is of utmost 
importance in early identification of this Condition . 
 
EPIDEMIOLOGY 
In many trials its prevalence is estimated as 19 -26%  but 
actual  prevalence of DbCM is not fully estimated. Prevalence of 
diastolic dysfunction in one study around 30% In other studies it is 
still more high.Various criteria for selection and imaging techniques 
may explain this disparity .  
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PATHOGENESIS AND PATHOPHYSIOLOGY  
It is not fully defined yet .It is multifactorial .Various proposed 
mechanisms include 1) metabolic 2) insulin resistance 3) cardiac 
autonomic dysfunction and myocardial fibrosis  4) alterations in 
RAAS .  
 
METABOLIC MECHANISM  
HYPERGLYCEMIA AND HEART  
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LIPID METOBOLISM AND HEART  
 
 
 
Cardiac steatosis is recently proposed mechanism for 
DbCM. 
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ROLE OF HYPERINSULINEMIA AND INSULIN 
RESISTANCE  
          Cardiac myocyte hypertrophy  results due to 
hyperinsulinemia. BNP is a marker of cadiac myocyte hypertrophy 
.Genetic alterations occurs as of it  leading to activation of 
transcriptional factors and to hypertrophy and deposition of ECM  
cause focal fibrosis in heart of diabetic patients . 
CONTRIBUTION FROM MICROVASCULAR ISCHEMIA 
          Ischemia leads to myocardial rigidity, scaring andcardiac 
dysfunction in DbCM . Microvascular complications of diabetes are 
diabetic retinopathy and neuropathy. In diabetes  ischemia resulting 
from microvascular disease affects  vasa vasorum  further damages 
medium arterioles  and small arterioles of the diabetic heart . 
ROLE OF RAAS   
          High blood glucose  stimulates intra-cardiac RAS.It  show 
various effects on  myocardial cells. Intracellular AGT  levels are 
found to be 3-4fold higher  in  cardiac muscle cell  of diabetic 
patients when  compared to normal individual.  
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CAN AND DbCM   
         Because of abnormalities in heart rate and vascular 
hemodynamics DbCM is a common complication . It is seen in 
longer duration of diabetes .Its prevalence is higher in diabetes . 
Patients with cardiac autonomic neuropathy are found to have 
decrease in  vascular elasticity and  increase in peripheral  vascular 
resistance due to abnormal sympathetic tone. Reduction of  
myocardial perfusion reserve  was shown  by few investigators. This 
will partly explain  ventricular dysfunction  related with diabetic 
CAN. 
          Diabetes causes structural change functional alterations in 
cardiomyopathy. It is divided into three stages .They are early 
,middle and late stage. Cardiac changes at molecular level will be 
seen in early stage there will be diastolic dysfunction and 
hypertrophy of  ventricles .ejection fraction is normal. 
           Middle stage  is a continuously progressive disease 
.Myocardial fibrosis  occurs and progressing ventricular hypertrophy 
results. Systolic dysfunction starts to occur along with diastolic 
dysfunction. In late stage it deteriorates further. 
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Diagnostic evaluation of DbCM  
           Diabetic cardiomyopathy in early stage will have subclinical 
features in the form of cardiomyocyte damage .It is detected by 
strain or tissue Doppler. Later stage can be diagnosed by our routine 
2D echo .  
ECHOCARDIOGRAPHY  
          Echocardiography is a cost effective simple diagnostic tool .It 
identifies structural and fuctional changes of heart .Usually 
ventricular diastolic function is assessed by blood flow across mitral 
valve using pulse Doppler. 
          During echo E/A is measured . It is the ratio between early 
ventricular filling /late ventricular filling Based on ratio it is graded 
as normal I/II/III  . But it has low sensitivity and specificity 
            We can use tissue dopper for regional motion abnormality 
Newer technics have come into field MIBG MRI can be done to 
assess diastolic dysfunction. 
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MATERIALS AND METHODS 
 
 
STUDY DURATION 
 
This study was done over a period of six months. 
 
STUDY POPULATION 
 
 
          The study comprised of type 2 Diabetes Mellitus    patients 
visiting the Outpatient(OP) department of institute of diabetology,or 
medical OP institute of internal medicine, Rajiv Gandhi Government 
General Hospital(RGGGH )and Madras Medical College, Chennai. 
Age and sex matched healthy volunteers served as controls. 
 
Sample Size 
  
Total Number of Subjects : 200 
Number of controls : 100 
 
Number of  
Type 2 Diabetes Mellitus cases : 100 
 
 
TYPE OF STUDY 
 
Observational study 
  
 
ETHICS COMMITTEE APPROVAL: 
 
Obtained. 
 
INCLUSION CRITERIA   
 1.Patients of type 2 diabetes  
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Exclusion Criteria  
1.Ischaemic Heart Disease/structural heart diseases  
2.Patients on pacemakers                                                                                                     
3.Chronic obstructive pulmonary disease                                                               
4.Secondary Diabetes Mellitus  
5.Anti-hypertensive and Anti-arrhythmic drugs                                             
6.Dyselectrolytemia                                                                                    
7.Hyperthyroidism or hypothyroidism  
8.Type1 Diabetes  
9.Gestational diabetes  
DATA COLLECTION AND METHODS 
METHODOLOGY 
Data collected from all those who fulfilled the inclusion 
and exclusion criteria after taking a detailed case history and 
obtaining a written informed consent. 
METHOD OF COLLECTION OF DATA 
          Baseline data including age and sex, detailed medical history 
including conventional risks factors, clinical examinations and 
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relevant investigations are included as part of the methodology. For 
all the subjects standing height and weight were measured. Hundred  
patients of type 2 diabetes mellitus of more than five years duration 
and 100 age and sex matched controls without any history of 
diabetes were  selected .Cardiac autonomic  function tests will be 
done in all cases and controls.Cases and controls were undergone 
Echocardiography .Cases  with diastolic dysfunction were subjected 
to cardiac stress testing to exclude  ischemic disease.  QTc 
dispersion were  measured and compared with diastolic dysfunction  
among patients with and without autonomic neuropathy and controls  
Product / Procedure / Investigation Details  
          1.12 lead simultaneous electrocardiograms (ECG).                                                                                  
          2. Manual measurement of QT interval and RR interval; and 
QTD  
         will be calculated using Bazets formula  
          3.Cardiovascular Autonomic Function tests with CANS 
analyzer                                
          4. 2DEchocardiography 
          5. Cardiac  stress testing (If applicable )  
 
47 
 
 
 
 
INTERPRETATION OF THE TEST WAS BASED ON THE WORKS OF 
EWING AND CLARKE16 
 
 
 Heart rate variability test Blood pressure test 
      
Score Deep Valsalva Response to Response to Response 
 to 
 breathing Ratio standing handgrip 
 
standing 
     
      
0 >15 >1.20 >15 >15 ≤ 10 
      
1 11-15 1.11-1.20 12-15 11-15 11-29 
      
2 ≤ 10 ≤1.10 <12 ≤ 10 >30 
      
 
 
 
For grading of cardiovascular autonomic function, results are 
classified into normal, mild and severel (scores 0,1,2 respectively). An overall 
score of ‘0’ or ‘1’ was considered normal, score 2,3,4 were considered mild 
and score ≥5 were judged was severel autonomic function56. 
 
          QT interval was taken from the onset of QRS complex to the end of T 
wave. QT was then corrected for heart rate using the Bazette’s formule44. 
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          QTc interval = QT / √(R – R). A QTc interval more than 440 
Millisecond is considered prolonged. 
 
 
          All the data will be entered in proforma(enclosed).The statistical 
software using SPSS version 20.0 was used for the analysis of data and 
MS word and Excel have been used to generate graphs, tables etc.  
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OBSERVATION AND RESULTS 
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OBSERVATION AND RESULTS 
          The present study was done to evaluate the prevalence of 
cardiac autonomic neuropathy in type 2 diabetes mellitus . 100 cases 
of type 2 diabetic cases were considered for this study and 100 age 
and sex matched healthy individuals were chosen as controls. The 
mean age of control and cases are presented in table 1A. A sex wise 
distribution of control and study groups are shown in table 1B. 
     
AGE DISTRIBUTION 
 
Age Group in years (CASES) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Age Group in years n % 
31-40 9 9.0 
41-50 43 43.0 
51-60 42 42.0 
61-70 6 6.0 
Total 100 100.0 
51 
 
 
 
 
 
SEX DISTRIBUTION 
 
 
         SEX DISTRIBUTION IN CASES  
 
 
SEX DISTRIBUTION IN 
CASES n % 
Male 58 58.0 
Female 42 42.0 
Total 100 100.0 
 
 
 
 
 
 
Age Group in years
61-70
51-60
41-50
31-40
52 
 
 
 
 
 
 Age Group in years (CONTROLS) 
 
Age Group in 
years n % 
31-40 5 5.0 
41-50 37 37.0 
51-60 54 54.0 
61-70 4 4.0 
Total 100 100.0 
 
 
 
 
Sex
Female
Male
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Sex (CONTROLS) 
 
Sex n % 
 
Male 61 61.0 
 
Female 39 39.0 
 
 
Total 100 100.0 
 
 
 
 
 
 
 
 
Age Group in years
61-70
51-60
41-50
31-40
54 
 
Sex (CONTROLS) 
 
 
 
 
 
  
Sex
Female
Male
55 
 
CARDIAC AUTONOMIC NEUROPATHY IN CASES 
 
 
  CAN Grade Total  
 
 
 
 
      P  
     value 
 
     0.000** 
  
Norm
al Mild 
Sever
e  
Age Group 
in years 
31-40 Count 6 3 0 9 
  % within 
Age Group 
in years 
66.7
% 
33.3
% .0% 
100.0
% 
  % within 
CAN Grade 
11.1
% 7.0% .0% 9.0% 
 41-50 Count 34 8 1 43 
    % within 
Age Group 
in years 
79.1
% 
18.6
% 2.3% 
100.0
% 
    % within 
CAN Grade 
63.0
% 
18.6
% 
33.3
% 43.0% 
  51-60 Count 14 26 2 42 
    % within 
Age Group 
in years 
33.3
% 
61.9
% 4.8% 
100.0
% 
    % within 
CAN Grade 
25.9
% 
60.5
% 
66.7
% 42.0% 
  61-70 Count 0 6 0 6 
    % within 
Age Group 
in years 
.0% 100.0% .0% 
100.0
% 
    % within 
CAN Grade .0% 
14.0
% .0% 6.0% 
Total Count 54 43 3 100 
  % within 
Age Group 
in years 
54.0
% 
43.0
% 3.0% 
100.0
% 
  % within 
CAN Grade 
100.0
% 
100.0
% 
100.0
% 
100.0
% 
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CARDIAC AUTONOMIC NEUROPATHY IN CASES 
 
 
 
 
  
Age Group in years
61-7051-6041-5031-40
Co
u
n
t
40
30
20
10
0
CAN Grade
Normal
Mild
Severe
57 
 
SEX DISTRIBUTION AND CAN 
 
  
CAN Grade 
Total Normal Mild Severe 
Sex Male Count 33 24 1 58 
% within 
Sex 56.9% 41.4% 1.7% 100.0% 
% within 
CAN 
Grade 
61.1% 55.8% 33.3% 58.0% 
Female Count 21 19 2 42 
% within 
Sex 50.0% 45.2% 4.8% 100.0% 
% within 
CAN 
Grade 
38.9% 44.2% 66.7% 42.0% 
Total Count 54 43 3 100 
% within 
Sex 54.0% 43.0% 3.0% 100.0% 
% within 
CAN 
Grade 
100.0% 100.0% 100.0% 100.0% 
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SEX DISTRIBUTION AND CAN 
 
 
 
                       
  
Sex
FemaleMale
Co
u
n
t
40
30
20
10
0
CAN Grade
Normal
Mild
Severe
59 
 
Duration of Diabetes in years 
 
Duration in 
years n % 
5-10 75 75.0 
Above 10 25 25.0 
Total 100 100.0 
 
 
DURATION OF DIABETES AND CAN 
 
 
CAN Grade Total 
  
 
 
P           
          
VALUE 
0.000** 
  
Nor
mal Mild 
Sever
e  
Duratio
n of 
Diabete
s 
5-10 Count 
54 20 1 75 
  % within Duration 
of Diabetes 
72.
0% 26.7% 1.3% 
100.0
% 
  % within CAN 
Grade 
100
.0% 46.5% 33.3% 75.0% 
 Abo
ve 
10 
Count 
0 23 2 25 
  % within Duration 
of Diabetes .0% 92.0% 8.0% 
100.0
% 
  % within CAN 
Grade .0% 53.5% 66.7% 25.0% 
Total Count 54 43 3 100 
 % within Duration 
of Diabetes 
54.
0% 43.0% 3.0% 
100.0
% 
 % within CAN 
Grade 
100
.0% 
100.0
% 
100.0
% 
100.0
% 
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DURATION OF DIABETES AND CAN 
 
 
 
 
 
  
Duration of Diabetes
Above 105-10
Co
u
n
t
60
50
40
30
20
10
0
CAN Grade
Normal
Mild
Severe
61 
 
 
QTc  DISPERSION IN CASES AND CAN  
 
  
  CAN Grade Total  
  
Norm
al Mild Severe  
 
QTD <= 
0.65 
Count 46 5 0 51  
  % within 
QTD 
90.2% 9.8% .0% 100.0% 
 
 
P 
VAL
UE 
0.000
** 
  % within 
CAN 
Grade 
85.2% 11.6% .0% 51.0% 
 
 > 0.65 Count 8 38 3 49  
  % within 
QTD 16.3% 77.6% 6.1% 
100.0
% 
 
  % within 
CAN 
Grade 
14.8% 88.4% 100.0% 49.0% 
 
Total Count 54 43 3 100  
 % within 
QTD 54.0% 43.0% 3.0% 
100.0
% 
 
 % within 
CAN 
Grade 
100.0
% 
100.0
% 
100.0
% 
100.0
% 
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QTc  DISPERSION IN CASES AND CAN  
 
   
 
 
 
 
 
                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
QTD
> 0.65<= 0.65
Co
u
n
t
50
40
30
20
10
0
CAN Grade
Normal
Mild
Severe
63 
 
QTD AND LVDD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  LVDD Grade Total  
  
Norma
l 
Grade 
I 
Grade 
II  
 
QTD <= 0.65 Count 46 5 0 51  
  % within 
QTD 90.2% 9.8% .0% 
100.0
% 
 
  % within 
LVDD 
Grade 85.2% 11.4% .0% 51.0% 
P 
VALU
E 
O.OO
O** 
 > 0.65 Count 8 39 2 49  
  % within 
QTD 16.3% 79.6% 4.1% 
100.0
% 
 
  % within 
LVDD 
Grade 
14.8% 88.6% 100.0% 49.0% 
 
Total Count 54 44 2 100  
 % within 
QTD 54.0% 44.0% 2.0% 
100.0
% 
 
 % within 
LVDD 
Grade 
100.0
% 
100.0
% 
100.0
% 
100.0
% 
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QTD AND LVDD 
 
 
 
 
 
 
HbA1C AND CAN 
 
 
 N Mean 
Std. 
Deviation 
 
 
 
 
P VALUE 
0.000** 
    
Normal 54 6.815 .2528 
Mild 43 6.279 .6289 
Severe 3 6.767 .0577 
Total 100 6.583 .5221 
 
 
QTD
> 0.65<= 0.65
Co
u
n
t
50
40
30
20
10
0
LVDD Grade
Normal
Grade I
Grade II
65 
 
 
BMI AND CAN : 
 
 
 
 N Mean Std. Deviation 
 
P VALUE 
0.000** 
    
Normal 54 27.52 2.081 
Mild 43 25.02 3.090 
Severe 3 29.67 1.528 
Total 100 26.51 2.869 
 
 
 
Concept of P value 
 
 
          If the P value is  0.000 to  0.010 then denoted by ** it imply 
Significant at 1 level (Highly Significant ) 
          If the P value is 0.011 to 0.050 then denoted by * it imply 
Significant at 5 level (Significant ) 
          If the P value is 0.051 to 1.000 then do not put star it imply 
Not Significant at 5 level (Not Significant) 
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RESULTS 
 
          This study consists of 100 type 2 diabetic patients and 100 age 
and sex matched healthy controls .Among 100 patients  9% between 
31-40 years of age 43% between 41-50 years 42% between 51-60 
years 6% were between 61-70 years of age. 58% were males . 
remaining were females ECG ,CAN FUNCTION assessed using 
analyser , ECHO were done for them . The prevalence of can in 
study group is high .This study showed significant relation between 
QTD ,CAN grades and LVDD. 
 
          Cardiac autonomic neuropathy more common with longer 
duration of diabetes. It is associated with obesity and glycemic 
control. Its  incidence  increases  with  age .More common among 
50-60 years of age.  
 
          Prevalence of diastolic dysfunction assessed by 2D echo is 46 
% . It is relatively higher incidence in diabetics than healthy 
individuals.Its incidence also increases with age and duration of 
diabetes  
          There is a significant association with prolongation of QT 
interval and cardiac autonomic neuropathy . There is association 
between cardiac  autonomic neuropathy and  diastolic dysfunction .  
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DISCUSSION 
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DISCUSSION 
          Cardiovascular  diseases  makes a  major list of the 
complications of diabetes  and its mortality .cardiac autonomic 
neuropathy, ischemic heart  disease and diabetic cardiomyopathy  
are direct complications of diabetes.Risk of heart failure  are two to 
three fold larger in diabetes when compared to non diabetes . DbCM 
is one of the  most common but underevaluated  cause of  cardiac 
failure in  type 2 diabetes. The pathology of diabetic cardiomyopathy 
is yet to be explained clearly . In the early stages of the disease 
diastolic dysfunction is the only abnormality. 2D echo is used to 
assess diastolic dysfunction. 
         QT dispersion, that reflects spatial inhomogeneity   in 
ventricular repolarization are associated with increased risk of 
certain arrhythmias and sudden cardiac death in type 2 diabetic 
patients and general population.  
          Several studies, but not all, have found a significantly greater 
QT dispersion in diabetics Pappachan J M et al studied the utility of 
prolongation of corrected QT  interval (QTc) in the ECG to diagnose 
CAN in patients with diabetes. They calculated the sensitivity and 
specificity of QTc prolongation for the diagnosis of CAN were 77% 
and 62.5% in type 1 and 76.5% and 75% in type 2, respectively.  
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         They concluded that QTc interval in ECG can be used to 
diagnose CAN with reasonable sensitivity and specificity. This value 
of sensitivity and specificity correlates with our study. 
          In another study by jayaprasad et al found association between 
QTD   and cardiac autonomic neuropathy in diabetes . In  that study 
among 50  patients  42%  had severe autonomic neuropathy and 24% 
had early autonomic  neuropathy. 
          Psallas et al conducted a study  which showed  QTD predict 
mortality in diabetes and it is associated with worsr prognosis . 
          Patients  in our hospital showed high prevalence of 
cardiovascular risk factors such as  obesity and poor glycemic 
control.This situation offers a opportunity to study the effect of QTD 
as a proxy for electrophysiological phenomenon.our study shows the 
deleterious effect of such risk factors on QTD particularly in long 
standing diabetes. 
          In multivariate analysis  QTD was predicted by sex, age ,BMI 
and HbA1C. 
          As expected patients with diabetes had higher risk of 
developing QT prolongation than in non diabetics . 
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          In a meta analysis recently concluded that  measurementof  
QTD is a more accurate test for autonomic failure in diabetes. 
Hyperglycemia  causes ventricular instability by increased 
sympathetic activation.   
           In our study there is no correlation among sex smoking 
alcohol with QTD or CAN. In some other study conducted showed 
significant association of sex and QT prolongation.   
          C P Mathur et al studied 50 patients with diabetes with  
20 normal controls to understand the relationship to CAN with QTc 
interval. There were 15 (78.94%) cases with QTc prolongation out 
of 19 diabetics with CAN. None of the diabetics without CAN or 
control subjects had QTc prolongation. It was observed to have 
sensitivity o9f 82.6% and specificity of 100%. This value of 
sensitivity matches the with our study but it does not correlates with 
specificity value. 
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CONCLUSIONS 
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CONCLUSIONS 
 
Prevalence of cardiac autonomic neuropathy is high in long 
standing diabetics  and rises with duration of diabetes. Its incidence is 
associated poor glycemic control and obesity. 
 
QTC dispersion is significantly high in diabetics with autonomic 
neuropathy .QTc prolongation and QT dispersion are useful  
parameters in high risks groups to identify cardiac autonomic 
neuropathy .It is simple non invasive and cost effective diagnostic 
tool.By using these tool we can identify subset of people who are at 
risk of sudden cardic death.  
 
Echocardiography is a standard diagnostic tool in diagnosing 
DbCM. DbCM is poorly understood complication in longstanding 
diabetics . It is associated with high morbidity and mortality. Clinical 
manifestations varies from subclinical ventricular dysfunction to 
congestive heart failure.  
 
Cardiac autonomic neuropathy correlates with diastolic 
dysfunction so that we can identify diabetic patients who are more 
prone to develop DbCM   later  in sub clinical condition by using 
simple tool  ECG and ECHO .We  can decrease morbidity in that 
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patients by frequent follow up and adequate management.    
 
Cardiac autonomic neuropathy  can form the basis for non 
ischemic diabetic cardiomyopathy . The confirmation of the presence 
of CAN in otherwise healthy type 2 diabetes patients, and its 
independent association with resting diastolic dysfunction, is 
important. 
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LIMITATIONS OF THE STUDY 
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LIMITATIONS OF THE STUDY 
 
The study size is small, and hence necessitates the need of a larger 
study with wide range of study population.  
 
           Lack of clinical follow up study . Mortality such as sudden cardiac 
death cannot be assessed so that we can confirm the influences of 
autonomic neuropathy Silent ischemia cannot be ruled out by coronary 
angiogram .More adverse clinical status  of  patients with CAN makes it 
difficult to isolate the direct effects of this complication on LV function, 
even after statistical adjustment.  Congenital long QT syndrome cannot be 
ruled out .  
 
 
 
 
BIBILOGRAPHY 
 
1. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic 
autonomic neuropathy. Diabetes Care 2003;26:1553-79. 
2. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic 
neuropathy.Circulation 2007;115:387-97. 
3. Kahn JK, Sisson JC, Vinik AI. Prediction of sudden cardiac 
death in diabetic autonomic neuropathy. J Nucl Med 
1988;29:1605-6. 
4. Sawicki PT, Dähne R, Bender R, Berger M. Prolonged QT 
interval as a predictor of mortality in diabetic nephropathy. 
Diabetologia 1996;39:77-81. 
5. Ewing DJ, Boland O, Neilson JM, Cho CG, Clarke BF. 
Autonomic neuropathy, QT interval lengthening, and unexpected 
deaths in male diabetic patients. Diabetologia 1991;34:182-5. 
6. Arildsen H, May O, Christiansen EH, Damsgaard EM. Increased 
QT dispersion in patients with insulin-dependent diabetes 
mellitus. Int J Cardiol 1999;71:235-42. 
7. Sivieri R, Veglio M, Chinaglia A, Scaglione P, Cavallo-Perin P. 
Prevalence of QT prolongation in a type 1 diabetic population 
and its association with autonomic neuropathy. The Neuropathy 
Study Group of the Italian Society for the Study of Diabetes. 
Diabet Med1993;10:920-4. 
8. Veglio M, Borra M, Stevens LK, Fuller JH, Perin PC. The 
relation between QTc interval prolongation and diabetic 
complications: The EURODIAB IDDM Complications Study 
Group. Diabetologia 1999;42:68-75. 
9. Takebayashi K, Aso Y, Sugita R, Takemura Y, Inukai T. 
Clinical usefulness of corrected QT intervals in diabetic 
autonomic neuropathy in patients with type 2 diabetes. Diabetes 
Metab 2002;28:127-32. 
10. Ewing DJ, Martyn CN, Young RJ, Clarke BF. The value of 
cardiovascular autonomic function tests: 10 years experience in 
diabetes. Diabetes Care 1985;8:491-8. 
11. Pfeifer MA, Weinberg CR, Cook DL, Reenan A, Halter JB, 
Ensinck JW, et al. Autonomic neural dysfunction in recently 
diagnosed diabetic subjects. Diabetes Care 1984;7:447-53. 
12. Vinik AI, Erbas T. Recognizing and treating diabetic autonomic 
neuropathy. Cleve Clin J Med 2001;68:928-30, 932, 934-44. 
 
13. Ziegler D. Diabetic cardiovascular autonomic neuropathy: 
Prognosis, diagnosis and treatment. Diabetes Metab Rev 
1994;10:339-83. 
14. Kahn R. Proceedings of a consensus development conference on 
standardized measures in diabetic neuropathy. Autonomic 
nervous system testing. Diabetes Care 1992;5:1095-103. 
15. Whitsel EA, Boyko EJ, Siscovick DS. Reassessing the role of 
QTc in the diagnosis of autonomic failure among patients with 
diabetes: A meta-analysis. Diabetes Care 2000;23:241-7. 
16. Jermendy G, Koltai MZ, Pogátsa G. QT interval prolongation in 
type 2 (non-insulin-dependent) diabetic patients with cardiac 
autonomic neuropathy. Acta Diabetol Lat 1990;27:295-301. 
17. Shimabukuro M, Chibana T, Yoshida H, Nagamine F, Komiya I, 
Takasu N. Increased QT dispersion and cardiac adrenergic 
dysinnervation in diabetic patients with autonomic neuropathy. 
Am J Cardiol 1996;78:1057-9. 
18. Landstedt-Hallin L, Englund A, Adamson U, Lins PE. Increased 
QT dispersion during hypoglycaemia in patients with type 2 
diabetes mellitus. J Intern Med 1999;246:299-307. 
 
19. Schönauer M, Thomas A, Morbach S, Niebauer J, Schönauer U, 
Thiele  H. Cardiac autonomic diabetic neuropathy. Diabetes 
Vasc Dis Res 2008;5: 336–44. 
20. Sacre JW, Franjic B, Jellis CL, Jenkins C, Coombes JS, Marwick 
TH.  Association of cardiac autonomic neuropathy with 
subclinical myocardial  Dysfunction in type 2 diabetes. J Am 
Coll Cardiol Img 2010; 3:1207–15. 
21. Nihal T, Vasan S, Bhatt R: A practical approach to Diabetes 
Mellitus, 2007  
22. Jayaram B M et al: Type 2 Diabetes Mellitus and its 
complications: A preventive program, 2008  
23. Vinik A I, Maser E R, Mitchell B D, Freeman R:Diabetic 
autonomic neuropathy. Diabetes Care 2003; 26:1553-1579  
24. Chen H S et al. Abnormal cardiovascular reflex tests are 
predictors of mortality in Type 2 diabetes. Diabetic Medicine 
2001; 18(4):268-273  
25. Aaron I. Vinik and Dan Ziegler: Diabetic Cardiovascular 
Autonomic Neuropathy. Circulation 2007;115;387-397  
 
26. Low .P.A, Walsh JC et al. The sympathetic nervous system in 
diabetic neuropathy, a clinical and pathological study. Brain 
1975, 98: 341– 56. 
27. Maser RE, Mitchell BD, et al. The associated between cardio 
vascular autonomic neuropathy and mortality in individuals with 
diabetes: a Meta – analysis. Diabeties care 2003; 26: 1895– 901.  
28. Burgos LG, Ebert TJ et al. Increased intra operative cardio 
vascular morbidity in diabetes with autonomic neuropathy. 
Anaesthesiology – 1989; 70: 591– 97.  
29. Duchen LW, Anjorin A et al. Pathology of autonomic 
neuropathy in DM. Ann. intern. Med. 1980; 92: 301.  
30. Becker, Klaus, Gorlach et al. Characterisation and natural course 
of cardiac autonomic neuron dysfunction 1997; 11(6): 751–757.  
31. Mc leod JG, Tuck RR; Disorders of the autonomic nervous 
system. Party I. Pathophysiology and clinical features. Part II 
investigation and treatment An Neurl. 21: 419, 519–1973.  
32. Adam and victor’s principles of neurology, McGraw – Hill 8th 
Edition  
33. .Gutrecht JA. Sympathetic skin response J. Clin. Neuro physiol. 
11: 519–1994  
34. Low PA, Clinical Autonomic Disorders 2nd ed. Philadelphia, 
Lippicott –Raven, 1997.  
35. Clarke BF, Ewing DJ, Campbell IW: Diabetic autonomic 
neuropathy. Diabetologia 1979; 17:195–212  
36. .F Bellavere, G Bosello, D Fedele, C Cardon e, and M Ferri Br 
Med J (Clin Res Ed). 1983 July 2; 287(6384): 61.  
37. Braunwald’s Heart disease, 7th edition ELSEVIER Saunders  
38. Aoron I Vinik et al Semi Neurol. 2003; 23: 365-372  
39. Textbook of Diabetes, John C Pickup & Gareth Williams, 3rd 
edition Blackwell Science  
40. Vinik AI, Erbas T: Neuropathy. In Handbook of Exercise in 
Diabetes. Ruderman N, Devlin JT, Schneider SH, Kriska A, Eds. 
Alexandria, VA, American Diabetes Association, 2002; 463–
496.  
41. Roy TM, Peterson HR, Snider HL, Cyrus J, et al.: Autonomic 
influence on cardiovascular performance in diabetic subjects. 
Am J Med 87:382–388, 1989.  
42. Vinik AI, Erbas T: Neuropathy. In Handbook of Exercise in 
Diabetes. Ruderman N, Devlin JT, Schneider SH, Kriska A, Eds. 
Alexandria, VA, American Diabetes Association, 2002; 463–
496.  
43. Hayat SA, Patel B, Khattar RS, Malik RA. Diabetic 
cardiomyopathy: mechanisms, diagnosis and treatment. Clin Sci 
(Lond). 2004;107: 539–557  
44. Didangelos TP, Arsos GA, Karamitsos DT, Athyros VG, 
Karatzas ND. Left ventricular systolic and diastolic function in 
normotensive type 1diabetic patients with or without autonomic 
neuropathy: a radionuclide ventriculography study. Diabetes 
Care. 2003;26:1955– 1960.  
45. Mustonen J, Uusitupa M, Lansimies E, Vainio P, Laakso M, 
Pyorala K. Autonomic nervous function and its relationship to 
cardiac performance in middle-aged diabetic patients without 
clinically evident cardiovascular disease. J Intern Med. 
1992;232:65–72.  
46. Lenzen MJ, Scholte op Reimer WJ, Boersma E, Vantrimpont PJ, 
Follath F, Swedberg K, Cleland J, Komajda M. Differences 
between patients with a preserved and a depressed left 
ventricular function: a report from the EuroHeart Failure Survey. 
Eur Heart J. 2004;25:1214 –1220.  
47. Ansari M, Alexander M, Tutar A, Massie BM. Incident cases  of  
heart failure  in  a  community  cohort:importance and outcomes 
of patients with preserved systolic function. Am Heart J. 
2003;146:115–120. 
48. Mandinov L, Eberli FR, Seiler C, Hess OM. Diastolic heart 
failure. Cardiovasc Res. 2000; 45: 813 – 825.  
49. Piccini JP, Klein L, Gheorghiade M, Bonow RO. New insights 
into diastolic heart failure: role of diabetes mellitus. Am J Med. 
2004; 116(suppl 5A):64S–75S.  
50. Ambepityia G, Kopelman PG, Ingram D, Swash M, Mills P: 
Exertional myocardial ischemia in diabetes: J Am Coll Cardiol 
1990; 15:72–77.  
QTc DISPERSION IN CARDIAC AUTONOMIC NEUROPATHY AND 
ITS CORRELATION WITH DIASTOLIC DYSFUNCTION IN TYPE 2 
DIABETES THE BASIS FOR NON ISCHEMIC  
CARDIOMYOPATHY ? 
 
PROFORMA 
Name:      Age/Sex: 
Address:      Occupation: 
Op Number: BMI : 
 
TYPE 2 DIABETES: 
            Duration: 
            Treatment:OHA/INSULIN/MEAL PLAN 
 
PAST HISTORY: 
 
COPD  
CVA  
CKD  
HYPERTENSION  
CAD  
PVD  
 
PERSONAL HISTORY: 
SMOKING 
ALCOHOL 
 
GENERAL EXAMINATION: 
 Pallor 
Icterus 
Cyanosis 
Clubbing 
Generalized lymphadenopathy 
Pedal edema 
 
 
 
VITAL SIGNS: 
       PR- 
       BP- 
 
SYSTEMIC  EXAMINATION: 
 
CVS: 
 
RS: 
 
ABDOMEN: 
 
CNS: 
 
INVESTIGATIONS: 
 
12 LEAD ECG 
 
2D ECHOCARDIOGRAPHY 
 
Cardiac stress testing if applicable 
  
  
  
 
 
TURNITIN ANTI PLAGIARISM – CERTIFICATE 
 
 
 
  
  
INFORMATION SHEET 
We are conducting a study on “QTc DISPERSION IN CARDIAC 
AUTONOMIC NEUROPATHY AND ITS CORRELATION WITH 
DIASTOLIC DYSFUNCTION IN TYPE 2 DIABETES THE BASIS 
FOR NON ISCHEMIC CARDIOMYOPATHY?” among patients 
attending Rajiv Gandhi Government General Hospital, Chennai and for that 
your specimen may be valuable to us. 
 
           The purpose of this study is to  study the prevalence and risk factors 
for cardiac autonomic neuropathy (CAN) and the utility of prolongation of 
corrected QT interval (QTc) in the ECG to diagnose CAN in patients with 
diabetes mellitus  and  to  identify  subset of diabetic patients who are at risk 
for sudden cardiac death and its correlation with diastolic dysfunction. 
 
We are selecting certain cases and if you are found eligible, we may be 
using your blood samples to do certain tests which in any way do not affect 
your final report or management. 
 
The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or presentation resulting 
from the research, no personally identifiable information will be shared. 
 
Taking part in this study is voluntary. You are free to decide whether 
to participate in this study or to withdraw at any time; your decision will not 
result in any loss of benefits to which you are otherwise entitled. 
 
The results of the special study may be intimated to you at the end of 
the study period or during the study if anything is found abnormal which may 
aid in the management or treatment. 
 
 
Signature of Investigator Signature of Participant 
( V.SUBASHINI) 
 
Date : 
Place : 
 
PATIENT CONSENT FORM 
Study Detail : “QTc DISPERSION IN CARDIAC AUTONOMIC 
NEUROPATHY AND ITS CORRELATION WITH 
DIASTOLIC DYSFUNCTION IN TYPE 2 DIABETES 
THE BASIS FOR NON ISCHEMIC 
CARDIOMYOPATHY?” 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
Identification 
Number 
:  
Patient may check (√) these boxes 
a) I confirm that I have understood the purpose of procedure for the 
above study. I have the opportunity to ask question and all my 
questions and doubts have been answered to my complete satisfaction. ❏ 
b) I understand that my participation in the study is voluntary and that I 
am free to withdraw at any time without giving reason, without my 
legal rights being affected. ❏ 
c) I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities 
will not need my permission to look at my health records, both in 
respect of current study and any further research that may be 
conducted in relation to it, even if I withdraw from the study I agree to 
this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published, 
unless as required under the law. I agree not to restrict the use of any 
data or results that arise from this study. ❏ 
d) I agree to take part in the above study and to comply with the 
instructions given during the study and faithfully cooperate with the 
study team and to immediately inform the study staff if I suffer from 
any deterioration in my health or well being or any unexpected or 
unusual symptoms. ❏ 
e) I hereby consent to participate in this study. ❏ 
f) I hereby give permission to undergo detailed clinical examination and 
blood investigations as required. ❏ 
 
Signature/thumb impression 
  
Patient’s Name and Address:
Signature of Investigator 
 
Study Investigator’s Name: 
Dr. SUBASHINI .V. 
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